OncLive highlights key advances in ovarian, Hodgkin lymphoma, pancreatic, melanoma and myelofibrosis therapies

The weekly "Five Under 5" roundup from OncLive curates the most notable oncology video content released during the first week of May. It spotlights recent data across a range of cancer types, offering clinicians a quick digest of emerging insights.

In ovarian cancer, a study of relacorilant combined with nab‑paclitaxel showed improved progression‑free and overall survival for patients with platinum‑resistant disease after prior bevacizumab, without requiring a biomarker test. For classical Hodgkin lymphoma, nivolumab plus AVD demonstrated superior progression‑free survival compared with brentuximab vedotin plus AVD, while maintaining low rates of severe immune‑mediated toxicity. In pancreatic cancer, the RAS‑mutant‑targeted agent daraxonrasib provided a significant interim overall‑survival benefit in previously treated metastatic patients, prompting further evaluation in earlier‑line settings.

The videos also discuss evolving strategies in myelofibrosis, emphasizing personalized JAK‑inhibitor selection and the ongoing debate over optimal timing for stem‑cell transplantation, the only potentially curative option. Together, these updates reflect a broader trend toward tailored therapies and highlight areas where additional research is needed.